The current head, John Crowley, a biotech executive and rare disease advocate, took over in March. GSK has spent slightly ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Prior to JWT/WT, North, Chauhan was the head of the agency's Sri Lanka operations and JWT (South). Chauhan has also worked at ...
GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.
GSK scored highly as its R&D programmes encompass ... with 19 integrating this into their overall corporate strategy," says the report, which also points to an increase in voluntary licensing ...
The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... from the PASO DOBLE study, a large head-to-head randomized clinical trial ...
the North office was responsible for numerous global and Indian brands like, PepsiCo, Nestle, GSK, Hero MotoCorp, Honda ...
The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...
EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback